News

Amer Zeidan, MBBS, discusses imetelstat and the IMerge/MDS3001 study of the agent in patients with lower-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.

According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.

Arlene O. Siefker-Radtke, MD, dives into the background and the cohorts included in the phase 3 THOR study.

The FDA issued a pair of complete response letters for the biologics license application for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

A novel CAR T-cell therapy being developed at City of Hope offers a potential new treatment avenue for patients with recurrent glioblastoma and high-grade glioma. 

In an interview, Raajit K. Rampal, MD, PhD, delved into the dynamic landscape of myelofibrosis therapy, highlighting treatment options beyond JAK inhibition.

A phase 2 trial plans to evaluate BAT8006 for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

This week's Targeted Pulse focuses on the latest in cervical cancer, the FDA ODAC's vote for cilta-cel, and more.

Kim N. Chi, MD, FRCPC, discusses results from the MAGNITUDE trial, including those on survival and patient-reported outcomes in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib plus abiraterone acetate and prednisone.

At a live virtual event, Michael McHale, MD, led a roundtable discussion on the use of PARP inhibition therapy for patients with advanced ovarian cancer.

In an interview with Targeted Oncology, Julie Chang, MD, discussed the minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma and the key findings from the trial.

Mirvetuximab soravatansine is now FDA-approved for the treatment of patients with folate receptor alpha-positive, platinum-resistant ovarian cancer

Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to findings from a phase 3b study.

Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.

The FDA strengthened safety warnings for fluorouracil due to dihydropyrimidine dehydrogenase deficiency that can cause severe adverse effects.

In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.

Raajit K. Rampal, MD, PhD, discusses some of the promising emerging therapies for myelofibrosis that target different pathways at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.

In an interview with Targeted Oncology, Elias Jabbour, MD, discussed the approval of ponatinib and what it means for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Lifileucel's FDA approval marks a breakthrough in melanoma treatment, offering hope with promising antitumor activity. While its potential extends to various solid tumors, challenges persist.

A fast track designation from the FDA has been given to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.

Ramez N. Eskander, MD, discusses additional targetable biomarkers that could be addressed in a similar combination as what was seen in the phase 3 NRG-GY018/KEYNOTE-868 trial with standard of care chemotherapy.

The combination of pembrolizumab and olaparib did not appear to improve overall or progression-free survival in patients with nonsquamous non-small cell lung cancer.

The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.

Thomas J. Herzog, MD, discusses the efficacy data seen in a subgroup analysis of the phase 2 AMPECT study evaluating nab-Sirolimus for patients with perivascular epithelioid sarcoma.

Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.

ctDNA offers clinicians the potential to determine whether to proceed with or discontinue PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer.

Thomas J. Herzog, MD, discusses the safety findings of nab-Sirolimus in a subgroup analysis of the phase 2 AMPECT study looking at patients with perivascular epithelioid sarcoma.

APL-1702 is the first nonsurgical treatment for cervical high-grade intraepithelial lesions to show clinical efficacy in a phase 3 trial, making it a potentially groundbreaking option in the field.